Results 161 to 170 of about 1,189,299 (292)

From Lab to Landscape: Environmental Biohybrid Robotics for Ecological Futures

open access: yesAdvanced Robotics Research, EarlyView.
This Perspective explores environmental biohybrid robotics, integrating living tissues, microorganisms, and insects for operation in real‐world ecosystems. It traces the leap from laboratory experiments to forests, wetlands, and urban environments and discusses key challenges, development pathways, and opportunities for ecological monitoring and ...
Miriam Filippi
wiley   +1 more source

ELABELA Targets Mitochondria to Modulate Heart Development

open access: yesAdvanced Science, EarlyView.
The role of peptide ELABELA (ELA) in cardiomyocyte apoptosis and congenital heart disease (CHD) is unclear. ELA deficiency caused cardiomyocyte apoptosis and CHD. A novel ELA‐APJ‐AKT‐BCL2/BAX axis in regulating mitochondrial function and contributing to CHD pathogenesis was established.
Jian Wang   +22 more
wiley   +1 more source

Consensus Formation and Change are Enhanced by Neutrality

open access: yesAdvanced Science, EarlyView.
Neutral agents are shown to enhance both the formation and overturning of consensus in collective decision‐making. A general mathematical model and experiments with locusts and humans reveal that neutrality enables robust consensus via simple interactions and accelerates consensus change by reducing effective population size.
Andrei Sontag   +3 more
wiley   +1 more source

Evaluating the Utilities of Foundation Models in Single‐Cell Data Analysis

open access: yesAdvanced Science, EarlyView.
This study delivers the first systematic, task‐level evaluation of single‐cell foundation models across eight core analytical tasks. By benchmarking 10 leading models with the scEval framework, it reveals where foundation models truly add value, where task‐specific methods still dominate, and provides concrete, reproducible guidelines to steer the next
Tianyu Liu   +4 more
wiley   +1 more source

Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy

open access: yesAdvanced Science, EarlyView.
A platinum(IV) prodrug is developed to systemically deliver the TLR7/8 agonist gardiquimod. Tumor‐targeting is mediated by an albumin‐binding maleimide, which limits premature complex activation. Ox‐Gardi‐Mal accumulates specifically in the tumor, where it activates the immune system.
Michael Gutmann   +15 more
wiley   +1 more source

Challenges and opportunities in financing urban primary healthcare in Iran: pathways to universal health coverage. [PDF]

open access: yesBMC Prim Care
Zamani-Nezhad L   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy